[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112021015479A2 - Anticorpos anti-trem1 e métodos relacionados - Google Patents

Anticorpos anti-trem1 e métodos relacionados

Info

Publication number
BR112021015479A2
BR112021015479A2 BR112021015479A BR112021015479A BR112021015479A2 BR 112021015479 A2 BR112021015479 A2 BR 112021015479A2 BR 112021015479 A BR112021015479 A BR 112021015479A BR 112021015479 A BR112021015479 A BR 112021015479A BR 112021015479 A2 BR112021015479 A2 BR 112021015479A2
Authority
BR
Brazil
Prior art keywords
trem1
related methods
trem1 antibodies
antibodies
methods
Prior art date
Application number
BR112021015479A
Other languages
English (en)
Inventor
Aritra Pal
Christopher Chan
G Presta Leonard
Linda Liang
Tu Le Tiep
Venkataraman Sriram
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of BR112021015479A2 publication Critical patent/BR112021015479A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos anti-trem1 e métodos relacionados. são fornecidos aqui anticorpos anti-trem1 e métodos relacionados de produção e uso de anticorpos anti-trem1. também são fornecidos métodos e composições para intensificar uma resposta imune e / ou para o tratamento de uma condição relacionada ao sistema imunológico em um indivíduo, por exemplo, câncer, compreendendo matar, desativar ou esgotar células mieloides não estimulatórias usando um anticorpo anti-trem1 ou fragmento de ligação ao antígeno do mesmo.
BR112021015479A 2019-02-06 2020-02-06 Anticorpos anti-trem1 e métodos relacionados BR112021015479A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802161P 2019-02-06 2019-02-06
US201962889994P 2019-08-21 2019-08-21
PCT/US2020/016949 WO2020163564A2 (en) 2019-02-06 2020-02-06 Anti-trem1 antibodies and related methods

Publications (1)

Publication Number Publication Date
BR112021015479A2 true BR112021015479A2 (pt) 2021-12-28

Family

ID=71947128

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015479A BR112021015479A2 (pt) 2019-02-06 2020-02-06 Anticorpos anti-trem1 e métodos relacionados

Country Status (18)

Country Link
EP (1) EP3921344A4 (pt)
JP (2) JP7492522B2 (pt)
KR (1) KR20210126638A (pt)
CN (1) CN113748132A (pt)
AU (1) AU2020218525A1 (pt)
BR (1) BR112021015479A2 (pt)
CA (1) CA3128053A1 (pt)
CL (1) CL2021002075A1 (pt)
CO (1) CO2021010887A2 (pt)
CR (1) CR20210462A (pt)
DO (1) DOP2021000165A (pt)
IL (1) IL284818A (pt)
MX (1) MX2021009500A (pt)
PE (1) PE20212269A1 (pt)
SG (1) SG11202108570SA (pt)
TW (1) TW202037613A (pt)
WO (1) WO2020163564A2 (pt)
ZA (1) ZA202210284B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220958A1 (en) 2023-04-21 2024-10-24 Celsius Therapeutics, Inc. Anti-trem1 antibody agents, compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN110256558B (zh) * 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
PL3653221T3 (pl) * 2015-02-19 2022-12-19 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
US10919968B2 (en) * 2016-01-29 2021-02-16 Modmab Therapeutics Corporation Frizzled5 protein-binding agents
EP3423493A2 (en) * 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
JP7184751B2 (ja) * 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用

Also Published As

Publication number Publication date
EP3921344A4 (en) 2022-10-12
CN113748132A (zh) 2021-12-03
ZA202210284B (en) 2023-03-29
KR20210126638A (ko) 2021-10-20
JP7492522B2 (ja) 2024-05-29
JP2024105632A (ja) 2024-08-06
JP2022523145A (ja) 2022-04-21
TW202037613A (zh) 2020-10-16
DOP2021000165A (es) 2021-09-30
WO2020163564A2 (en) 2020-08-13
CO2021010887A2 (es) 2021-09-09
WO2020163564A3 (en) 2020-09-24
AU2020218525A1 (en) 2021-09-23
CA3128053A1 (en) 2020-08-13
MX2021009500A (es) 2021-09-08
IL284818A (en) 2021-08-31
PE20212269A1 (es) 2021-11-30
SG11202108570SA (en) 2021-09-29
CR20210462A (es) 2021-12-13
EP3921344A2 (en) 2021-12-15
CL2021002075A1 (es) 2022-04-01

Similar Documents

Publication Publication Date Title
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
AR111362A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
BR112019007714A2 (pt) anticorpos de 4-1bb anti-humanos e usos dos mesmos
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
BR112018006531A2 (pt) proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112018071287A2 (pt) composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX2024010987A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
BR112021015479A2 (pt) Anticorpos anti-trem1 e métodos relacionados
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
EA202091458A1 (ru) Анти-trem2 антитела и связанные с ними способы
EA202191929A1 (ru) Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания
EA202090201A2 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
MX2021000268A (es) Anticuerpos contra especies de campylobacter.